Ixazomib

Search with Google Search with Bing

Information
Drug Name
Ixazomib
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
colorectal cancer KRAS MUTATION KRAS MUTATION D Predictive Supports Resistance Somatic 1 26709701 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical study in colorectal cancer xenografts.... KRAS KRAS MUTATION KRAS MUTATION Resitance or Non-Reponse true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03547700 Active, not recruiting Phase 1/Phase 2 Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) September 26, 2018 July 2021
NCT02004275 Active, not recruiting Phase 1/Phase 2 Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma February 2014
NCT04998786 Active, not recruiting Phase 2 A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." December 14, 2021 January 1, 2027
NCT04047797 Active, not recruiting Phase 2 Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma August 28, 2019 June 1, 2024
NCT02253316 Active, not recruiting Phase 2 Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma January 20, 2015 August 31, 2024
NCT02343042 Active, not recruiting Phase 1/Phase 2 Selinexor and Backbone Treatments of Multiple Myeloma Patients October 2015 April 2027
NCT02412228 Active, not recruiting Phase 2 Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma August 2015 September 2024
NCT04009109 Active, not recruiting Phase 2 Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM October 21, 2020 July 1, 2026
NCT03942224 Active, not recruiting Phase 2 Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma July 3, 2019 July 31, 2025
NCT02516423 Active, not recruiting Phase 3 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone December 2015
NCT03817320 Active, not recruiting Phase 1/Phase 2 PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma February 12, 2019 June 30, 2025
NCT03763162 Active, not recruiting Phase 2 Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma January 17, 2019 December 31, 2024
NCT02632396 Active, not recruiting Phase 1/Phase 2 Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission March 1, 2016 August 2024
NCT02765854 Active, not recruiting Phase 2 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement September 1, 2016 December 1, 2024
NCT03651128 Active, not recruiting Phase 3 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) April 16, 2019 April 8, 2027
NCT02916771 Active, not recruiting Phase 2 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma October 2016 April 8, 2025
NCT02924272 Active, not recruiting Phase 2 Ixazomib Rollover Study December 16, 2016 February 22, 2027
NCT03618537 Active, not recruiting Phase 2 Ixazomib Maintenance Study in Patients With AL Amyloidosis August 2, 2018 August 2026
NCT03173092 Active, not recruiting Phase 4 A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) November 13, 2017 November 30, 2026
NCT03225417 Active, not recruiting Phase 1/Phase 2 Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. May 16, 2017 December 31, 2024
NCT03283917 Active, not recruiting Phase 1 Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis February 7, 2018 May 18, 2025
NCT03376672 Active, not recruiting Phase 2 Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients May 31, 2018 December 31, 2027
NCT03590652 Active, not recruiting Phase 2 Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma October 17, 2018 October 1, 2025
NCT03587662 Active, not recruiting Phase 2 Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer August 17, 2018 January 31, 2025
NCT02400437 Completed Phase 2 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia April 2015 November 2019
NCT02410694 Completed Phase 2 Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma April 2015 May 2, 2019
NCT02917941 Completed Phase 2 A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma November 1, 2016 August 31, 2019
NCT02440464 Completed Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) August 2015 October 1, 2020
NCT03433001 Completed A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone April 2, 2018 June 11, 2021
NCT02942095 Completed Phase 1 Study of Ixazomib and Erlotinib in Solid Tumors March 6, 2017 December 7, 2022
NCT02499081 Completed Phase 2 UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment September 2015 May 17, 2018
NCT03323151 Completed Phase 1/Phase 2 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma August 13, 2018 September 7, 2023
NCT03082677 Completed Phase 2 Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies March 10, 2017 September 2, 2021
NCT03169361 Completed NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" May 24, 2017 March 8, 2022
NCT02630030 Completed Early Phase 1 Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma March 24, 2016 September 3, 2020
NCT03170882 Completed Phase 2 A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma August 1, 2017 November 26, 2021
NCT00893464 Completed Phase 1 A Study of IXAZOMIB in Adult Patients With Lymphoma August 2009 October 2014
NCT00932698 Completed Phase 1 Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma October 12, 2009 May 23, 2017
NCT01217957 Completed Phase 1/Phase 2 A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma November 22, 2010 February 2, 2018
NCT01318902 Completed Phase 1 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis April 27, 2011 November 13, 2018
NCT01335685 Completed Phase 1/Phase 2 Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma June 27, 2011 December 29, 2016
NCT01383928 Completed Phase 1/Phase 2 Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma October 31, 2011 November 27, 2017
NCT01564537 Completed Phase 3 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma August 1, 2012 February 8, 2022
NCT01645930 Completed Phase 1 Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma December 17, 2012 April 11, 2017
NCT00830869 Completed Phase 1 A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies March 2, 2009 April 20, 2012
NCT01830816 Completed Phase 1 Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment September 16, 2013 November 18, 2016
NCT01850524 Completed Phase 3 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma April 29, 2013 June 24, 2022
NCT01912222 Completed Phase 1 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction August 2013 March 2015
NCT01939899 Completed Phase 2 Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma October 31, 2013 March 23, 2017
NCT01953783 Completed Phase 1 Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB March 19, 2014 February 9, 2016
NCT03439293 Completed Phase 2 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) March 13, 2018 June 9, 2023
NCT02831686 Completed Phase 1 A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma July 2016 November 19, 2020
NCT02046070 Completed Phase 2 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma March 5, 2014 June 29, 2018
NCT02070458 Completed Phase 1 Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia October 8, 2014 August 15, 2017
NCT03748953 Completed Phase 3 Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) January 24, 2019 November 29, 2023
NCT03416374 Completed Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy February 18, 2018 May 28, 2021
NCT04028115 Completed Phase 2 Bone Healing During Ninlaro Exposure October 24, 2019 April 1, 2024
NCT02312258 Completed Phase 3 A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) April 9, 2015 August 26, 2022
NCT03236792 Completed Phase 1/Phase 2 Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis June 12, 2017 September 20, 2022
NCT06050512 Recruiting Phase 1/Phase 2 Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma October 2, 2023 October 2026
NCT03616782 Recruiting Phase 2 Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) December 24, 2018 May 31, 2026
NCT03669445 Recruiting Phase 2 Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma December 31, 2018 December 2024
NCT04052880 Recruiting Phase 2 Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM October 24, 2019 June 2025
NCT04094961 Recruiting Phase 1/Phase 2 Ixazomib + Pomalidomide + Dexamethasone In MM September 18, 2019 December 20, 2024
NCT05451771 Recruiting Phase 1/Phase 2 Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis October 26, 2022 September 2026
NCT05722405 Recruiting Phase 4 Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma July 1, 2022 July 31, 2025
NCT03733691 Terminated Phase 2 Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients March 1, 2019 October 19, 2023
NCT02897830 Terminated Phase 2 Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma August 5, 2016 August 31, 2020
NCT04079738 Terminated Phase 1/Phase 2 Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib September 20, 2019 February 23, 2022
NCT01659658 Terminated Phase 3 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis December 26, 2012 July 11, 2022
NCT04119336 Terminated Phase 2 Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma February 14, 2020 March 30, 2022
NCT04272775 Terminated Phase 1 A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) June 5, 2012 February 15, 2019
NCT03492138 Terminated Phase 1/Phase 2 Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma March 26, 2018 January 14, 2020
NCT04837131 Terminated Phase 2 A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients April 28, 2021 February 23, 2024
NCT02993094 Terminated Phase 1/Phase 2 Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer November 21, 2016 August 15, 2020
NCT02898259 Terminated Phase 1/Phase 2 Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma February 20, 2017 June 6, 2022
NCT02030405 Terminated Phase 2 Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia March 2014 November 2015
NCT02447887 Terminated Phase 1/Phase 2 Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) August 14, 2015 April 25, 2017
NCT02302846 Terminated Phase 2 Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission March 20, 2015 May 30, 2017
NCT02176486 Terminated Phase 1 Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) June 9, 2014 January 19, 2018
NCT02461888 Unknown status Phase 2 Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. December 2015 January 2021
NCT04217967 Unknown status Phase 4 Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients January 3, 2020 October 1, 2022
NCT03856112 Withdrawn Phase 1/Phase 2 Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma June 21, 2019 December 31, 2021
NCT03880123 Withdrawn Phase 1 Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma November 2020 November 24, 2020
NCT02578511 Withdrawn Phase 1 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) June 29, 2017 February 13, 2018
NCT05183139 Withdrawn Phase 4 A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma June 30, 2022 December 31, 2026
NCT03608501 Withdrawn Phase 2 A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation September 30, 2019 May 31, 2023
NCT03888534 Withdrawn Phase 1 Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) October 31, 2020 August 30, 2022
NCT02578121 Withdrawn Phase 2 UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination December 2015 January 2017